Ionis Pharmaceuticals Says Transthyretin-Mediated Amyloidosis Treatment Gets Approval in Europe

MT NewswiresMar 10 07:58 ET

Ionis and AstraZeneca Win EU Approval for WAINZUA, a Self-Injectable Treatment for Rare Nerve Disease

BenzingaMar 10 07:02 ET

Express News | Wainzua (Eplontersen) Approved in the EU for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults With Stage 1 or Stage 2 Polyneuropathy

ReutersMar 10 07:00 ET

Ionis to Present at Upcoming Investor Conferences

BusinesswireFeb 25 07:05 ET

Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $38

Moomoo NewsFeb 24 21:32 ET · Ratings

Stifel Nicolaus Remains a Hold on Ionis Pharmaceuticals (IONS)

TipRanksFeb 24 21:09 ET · Ratings